Semaglutide is a glp-1 receptor agonist with a development status of "fda-approved (branded forms)". The Institute rates the strength of its published evidence as strong. A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, supported by large randomized controlled trials.
The distinction that matters most when reading about Semaglutide is between what has been demonstrated and what has been proposed. Mechanistic plausibility is not evidence of effect, and a compound can have a well-characterised receptor interaction while producing no measurable clinical benefit. That gap is where most of the confusion in this space lives.
Where human data exists for Semaglutide, endpoints are frequently surrogate measures rather than outcomes people care about. A change in a biomarker is a reason to run a larger trial, not a reason to conclude the trial would succeed.
The Institute has independently tested 23 Semaglutide samples from 13 companies. 87% met their label claims on purity and content. Measured purity ranged from 58.1% to 99.1%, averaging 95.5%. 1 sample failed verification outright. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
